Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00073047 · ClinicalTrials.gov registry record · Phase 2
Humanized Anti-IL-2 Receptor Monoclonal Antibody in Moderate-to-severe Ulcerative Colitis
A Phase 2 study, sponsored by Facet Biotech.
- Completed
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
NCT00073047 is a Phase 2 study that has completed, run by Facet Biotech. The registered enrollment target is 150 participants.
The verdict
NCT00073047, a Phase 2 study, has completed, sponsored by Facet Biotech.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
Study Summary
The purpose of The PROSPECT Study is to evaluate an investigational medication for the treatment of moderate to severe ulcerative colitis. This study is being conducted at up to 38 clinical research centers in the US, Canada, and Belgium, and is open to male and female patients 12 years and older. Participants in the study will have a number of visits to a research center over a five-month period. All study related care and medication is provided to qualified participants at no cost: this includes all visits, examinations, and laboratory work.
Interventions
- DRUG Daclizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2003-04 |
| Est. Completion | 2006-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00073047
The ClinicalTrials.gov registry entry for NCT00073047 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Facet Biotech, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Daclizumab is the first listed.
NCT00073047 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00073047 about?
NCT00073047 is a clinical study titled "Humanized Anti-IL-2 Receptor Monoclonal Antibody in Moderate-to-severe Ulcerative Colitis". The purpose of The PROSPECT Study is to evaluate an investigational medication for the treatment of moderate to severe ulcerative colitis. This study is being conducted at up to 38 clinical research centers in the US, Canada, and Belgium, and is open to male and female patients 12 years and older. P...
What is the current status of trial NCT00073047?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2003-04. Estimated completion is 2006-07.
What interventions are being tested in trial NCT00073047?
The interventions under investigation include: Daclizumab (DRUG).
Who is sponsoring clinical trial NCT00073047?
This trial is sponsored by Facet Biotech, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.